We anticipate that future high-resolution structural studies seeking to characterize this conformation will lead to an improved understanding of TG2 biological and cellular signaling activities, and to an enhanced ability to design new small molecule inhibitors targeting the GTP-binding site of TG2 as well as more potent analogs of LM11 that will provide a therapeutic benefit to patients suffering from cancers exhibiting high TG2 expression. The gene discussed is TGM2; the disease is cancer.